UBC-test use in the capacity of urinary marker of bladder cancer
https://doi.org/10.20538/1682-0363-2009-2-113-117
Abstract
The enzyme immunoassay was used to evaluate diagnostic value of level of tumoral marker UBC at 54 patients with muscle invasive bladder cancer. The obtained data testify to possibility of use of the UBC-test for diagnostics primary bladder cancer, at monitoring for patients for revealing superficial and muscle invasive relapses after spent treatments. UBC it can be considered as the additional diagnostic marker, allowing to assume presence muscle invasive character of growth of a tumors, and also for an efficiency estimation neoadjuvant chemotherapy.
About the Authors
S. I. Vintizenko
НИИ онкологии СО РАМН
Russian Federation
Russian Federation
Ye. M. Slonimskaya
НИИ онкологии СО РАМН
Russian Federation
Russian Federation
Ye. A. Usynin
НИИ онкологии СО РАМН
Russian Federation
Russian Federation
S. L. Stukanov
НИИ онкологии СО РАМН
Russian Federation
Russian Federation
References
1. Маршутина Н.В., Сергеева Н.С., Стороженко И.В. и др. Оценка новых опухолевых маркеров TAG12, CA242 и UBC у онкологических больных//Материалы 5-го Всерос. съезда онкологов. Казань, 2000. С. 190-191.
2. Матвеев Б.П., Фигурин К.М., Корякин О.Б. Рак мочевого пузыря. М., 2001. 243 c.
3. Матвеенко А.А. Цитодиагностические критерии прогрессии рака мочевого пузыря//Материалы 5-го Всерос. съезда онкологов. Казань, 2000. С. 340-342.
4. Мационис А.Э., Матвеенко А.А., Медведева Л.А., Ягубянц Ю.Т. Поверхностный рак мочевого пузыря. Роль патолога//Материалы 4-й Всерос. конф. М., 2001. С. 30-38.
5. Меньшиков В.В. Качество клинических лабораторных исследований. М.: Москва, 2002. 304 с.
6. Переверзев А.С., Петров С.Б. Опухоли мочевого пузыря. Харьков: Факт, 2002. 303 с.
7. Сергеева Н.С., Родина И.А., Русаков И.Г. и др. Исследование UBC-антигена как возможного уринологического маркера рака мочевого пузыря//Рос. онкол. журн. № 1. 2004. С. 30-33.
8. Шелепова В.М. Клиническое значение определения растворимого фрагмента цитокератина 19-Cyfra 21-1//Лаборатория. 2004. № 2. C. 3-6.
9. Babjuk M., Kostirova M. and Mudra K. et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder//Eur. Urol. 2002. № 41. P. 34-39.
10. Вol M.G., Baak J.P., van Diermen B. et al. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomfs: identification of subgroups with low and high stage progression risk//J. Clin. Pathol. 2003. V. 56. P. 447-452.
11. Dai G., Wang X. Development of bladder cancer chemoprevention//Wei. Sheng. Yan. Jiu. 2003. V. 32. P. 159-162.
12. Mungan N.A., Vriesema J.L., Thomas C.M. et al. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer//Urology. 2000. P. 787-792.
13. Sanchez-Carbayo M., Herrero E., Megı.as J. et al. Comparative sensitivity of urinary CYFRA 21-1, UBC, TPA and NMP22 in the detection of bladder cancer//J. Urol. 1999. № 162. P. 1951-1956.
14. Yamashita S., Hoshi S., Ohyama C. et al. Urethral reccurence following neobladder in bladder cancer patients//Tohoku J. Exp. Med. 2003. V. 199. P. 197-203.
Review
For citations:
Vintizenko S.I., Slonimskaya Ye.M., Usynin Ye.A., Stukanov S.L. UBC-test use in the capacity of urinary marker of bladder cancer. Bulletin of Siberian Medicine. 2009;8(2):113-117. (In Russ.) https://doi.org/10.20538/1682-0363-2009-2-113-117
Views:
470
Email this article 